Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ludovic Samalin

Showing results (11-20 of 122) with videos related to

Pageof 13
Sort By:
Expert Review of Neurotherapeutics|February 9, 2010
Optimizing treatment of schizophrenia to minimize relapseLudovic Samalin, Olivier Blanc, Pierre-Michel Llorca
Journal of Epidemiology and Population Health|November 15, 2024
The digital mental health challenge in FranceLudovic Samalin, Frank Bellivier, Raymund Schwan, et al.
The Journal of Nervous and Mental Disease|April 1, 2011
Adherence to guidelines by French psychiatrists in their real world of clinical practiceLudovic Samalin, Sebastien Guillaume, Candy Auclair, et al.
Expert Opinion on Drug Safety|January 14, 2016
Olanzapine pamoate for the treatment of schizophrenia--a safety evaluationLudovic Samalin, Ricardo Garay, Ahcène Ameg, et al.
BMC Medical Education|March 4, 2026
Use of artificial intelligence-enhanced virtual patients in educational approaches to medical interview training: a systematic reviewValentin Gilbert, Pierre Philip, Pierre-Michel Llorca, et al.
Nordic Journal of Psychiatry|June 26, 2013
What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder?Ludovic Samalin, Aurore Nourry, Thomas Charpeaud, et al.
International Journal of Molecular Sciences|November 22, 2016
Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable AntipsychoticsLudovic Samalin, Marion Garnier, Candy Auclair, et al.
Pharmaceutics|December 23, 2023
The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic ReviewLudivine Boudieu, Myriam Mennetrier, Pierre-Michel Llorca, et al.
Expert Opinion on Investigational Drugs|November 26, 2014
Investigational drugs for anxiety in patients with schizophreniaRicardo P Garay, Ludovic Samalin, Ahcène Hameg, et al.
Plos One|March 4, 2017
Exploratory analysis of the French version of the beliefs about medicines questionnaire in patients with severe mental disorders: Factorial structure and reliability in specific populations of schizophrenic, bipolar and depressive patientsLudovic Samalin, Ingrid de Chazeron, Raoul Belzeaux, et al.
Pageof 13

Showing results (11-20 of 122) with videos related to

Sort By:
Pageof 13
Expert Review of Neurotherapeutics|February 9, 2010
Optimizing treatment of schizophrenia to minimize relapseLudovic Samalin, Olivier Blanc, Pierre-Michel Llorca
Journal of Epidemiology and Population Health|November 15, 2024
The digital mental health challenge in FranceLudovic Samalin, Frank Bellivier, Raymund Schwan, et al.
The Journal of Nervous and Mental Disease|April 1, 2011
Adherence to guidelines by French psychiatrists in their real world of clinical practiceLudovic Samalin, Sebastien Guillaume, Candy Auclair, et al.
Expert Opinion on Drug Safety|January 14, 2016
Olanzapine pamoate for the treatment of schizophrenia--a safety evaluationLudovic Samalin, Ricardo Garay, Ahcène Ameg, et al.
BMC Medical Education|March 4, 2026
Use of artificial intelligence-enhanced virtual patients in educational approaches to medical interview training: a systematic reviewValentin Gilbert, Pierre Philip, Pierre-Michel Llorca, et al.
Nordic Journal of Psychiatry|June 26, 2013
What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder?Ludovic Samalin, Aurore Nourry, Thomas Charpeaud, et al.
International Journal of Molecular Sciences|November 22, 2016
Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable AntipsychoticsLudovic Samalin, Marion Garnier, Candy Auclair, et al.
Pharmaceutics|December 23, 2023
The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic ReviewLudivine Boudieu, Myriam Mennetrier, Pierre-Michel Llorca, et al.
Expert Opinion on Investigational Drugs|November 26, 2014
Investigational drugs for anxiety in patients with schizophreniaRicardo P Garay, Ludovic Samalin, Ahcène Hameg, et al.
Plos One|March 4, 2017
Exploratory analysis of the French version of the beliefs about medicines questionnaire in patients with severe mental disorders: Factorial structure and reliability in specific populations of schizophrenic, bipolar and depressive patientsLudovic Samalin, Ingrid de Chazeron, Raoul Belzeaux, et al.
Pageof 13